4523 Stock Overview
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Eisai Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6,689.00 |
| 52 Week High | JP¥11,250.00 |
| 52 Week Low | JP¥5,795.00 |
| Beta | -0.062 |
| 1 Month Change | 9.12% |
| 3 Month Change | 1.26% |
| 1 Year Change | -15.64% |
| 3 Year Change | -1.75% |
| 5 Year Change | 6.60% |
| Change since IPO | 310.73% |
Recent News & Updates
Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly
Apr 11
Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00
Mar 18Shareholder Returns
| 4523 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 2.2% | -2.2% | -0.4% |
| 1Y | -15.6% | 6.8% | 27.4% |
Return vs Industry: 4523 underperformed the JP Pharmaceuticals industry which returned 6.3% over the past year.
Return vs Market: 4523 underperformed the JP Market which returned 27% over the past year.
Price Volatility
| 4523 volatility | |
|---|---|
| 4523 Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 4523 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4523's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1941 | 11,076 | Haruo Naito | www.eisai.co.jp |
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Eisai Co., Ltd. Fundamentals Summary
| 4523 fundamental statistics | |
|---|---|
| Market cap | JP¥1.92t |
| Earnings (TTM) | JP¥45.42b |
| Revenue (TTM) | JP¥749.46b |
42.2x
P/E Ratio2.6x
P/S RatioIs 4523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4523 income statement (TTM) | |
|---|---|
| Revenue | JP¥749.46b |
| Cost of Revenue | JP¥157.79b |
| Gross Profit | JP¥591.67b |
| Other Expenses | JP¥546.25b |
| Earnings | JP¥45.42b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 158.37 |
| Gross Margin | 78.95% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 19.7% |
How did 4523 perform over the long term?
See historical performance and comparison